Precision BioSciences, Inc. (DTIL)

Market Cap	92.19M +156.2%
Revenue (ttm)	698,000 -99.1%
Net Income	-83.60M
EPS	-8.32
Shares Out	24.07M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	145,364
Open	3.870
Previous Close	3.880
Day's Range	3.650 - 3.900
52-Week Range	3.650 - 8.820
Beta	1.31
Analysts	Strong Buy
Price Target	60.00 (+1,466.58%)
Earnings Date	Mar 25, 2026

About DTIL

Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits, as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Mar 28, 2019
• Employees: 67
• Stock Exchange: NASDAQ
• Ticker Symbol: DTIL
• Website: https://precisionbiosciences.com

Analyst Summary

According to one analyst, the rating for DTIL stock is "Strong Buy" and the 12-month stock price target is $60.0.

Price Target

$60.0

(1,466.58% upside)

Analyst Consensus: Strong Buy